Mina Tadrous
CanadaacademicMale5.0Global Dominance: 0.01%Mina Tadrous is a prominent researcher and Canada Research Chair in real world evidence at pharmaceutical policy at the University of Toronto. His work focuses on the intersection of pharmaceutical policy, healthcare economics, and drug safety, and he has contributed significantly to the understanding of how policy decisions impact drug availability and healthcare costs.
Country presence
Recent news mentions
Mina Tadrous is a pharmaceutical policy professor who discussed the challenges of cancer therapies in Ontario.
An Ontario family hopes their son’s death can change Canada’s cancer treatment review processCanada· 2026-06-01
Mina Tadrous, an associate professor at the University of Toronto’s pharmacy faculty, said switching a patient’s painkiller can take a lot of time and resources.
Canada’s shortage of prescription painkillers is expected to continue into the new yearCanada· 2025-11-04
Mina Tadrous is a pharmaceutical policy researcher who commented on the delays in drug reimbursement in Canada.
Canadians can wait years to get drugs regulators have already deemed safe. Why?Canada· 2025-10-31
Mina Tadrous, a Canada Research Chair in real world evidence and pharmaceutical policy at the University of Toronto, commented on the majority of drugs exported to the U.S.
Trump’s latest tariffs hit new group of Canadian industries, but details are hazyCanada· 2025-09-26
Mina Tadrous is a Canada Research Chair in Real World Evidence and Pharmaceutical Policy at the University of Toronto.
Moderna to roll out first made-in-Canada COVID-19 vaccines this fallCanada· 2025-09-19
Mina Tadrous, a Canada Research Chair in real world evidence and pharmaceutical policy at the University of Toronto, discussed the complexities of drug production.
U.S. puts drug tariffs on the table, threatening entire supply chainsCanada· 2025-04-16
Mina Tadrous, a Canada Research Chair in real world evidence at pharmaceutical policy at the University of Toronto, discussed the potential supply chain disruptions due to tariffs.
Trump’s proposed tariffs likely to cause shortages of Canadian-made drugs in U.S., study saysCanada· 2025-03-31
